Access to anti-retroviral drugs, female in Malaysia

Malaysia: Access to anti-retroviral drugs, female was 65.0% in 2024. ◆ Volatile

Latest (2024)
65.0%
Change on year
up 1.6%
World rank
91st
of 141 countries
All-time high
71.0%
in 2019
All-time low
1.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Malaysia, 2000–2024

0204060802000201220242000: 1 %2001: 1 %2002: 7 %2003: 13 %2004: 17 %2005: 21 %2006: 24 %2007: 27 %2008: 29 %2009: 31 %2010: 33 %2011: 35 %2012: 35 %2013: 40 %2014: 49 %2015: 51 %2016: 66 %2017: 70 %2018: 70 %2019: 71 %2020: 71 %2021: 67 %2022: 64 %2023: 64 %2024: 65 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Malaysia stood at 65.0%.

Compared with earlier readings it is up 1.6% on the previous year and up 32.7% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Malaysia peaked at 71.0% in 2019 and was at its lowest, 1.0%, in 2000.

Malaysia ranks 91st of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Malaysia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Malaysia, 2000 to 2024.
Year % Change
2000 1.0%
2001 1.0% +0.0%
2002 7.0% +600.0%
2003 13.0% +85.7%
2004 17.0% +30.8%
2005 21.0% +23.5%
2006 24.0% +14.3%
2007 27.0% +12.5%
2008 29.0% +7.4%
2009 31.0% +6.9%
2010 33.0% +6.5%
2011 35.0% +6.1%
2012 35.0% +0.0%
2013 40.0% +14.3%
2014 49.0% +22.5%
2015 51.0% +4.1%
2016 66.0% +29.4%
2017 70.0% +6.1%
2018 70.0% +0.0%
2019 71.0% +1.4%
2020 71.0% +0.0%
2021 67.0% -5.6%
2022 64.0% -4.5%
2023 64.0% +0.0%
2024 65.0% +1.6%

Averages by decade

DecadeAverage LowestHighest Years
2000s 17.1% 1.0% 31.0% 10
2010s 52.0% 33.0% 71.0% 10
2020s 66.2% 64.0% 71.0% 5

Countries ranked near Malaysia

  1. 88 Barbados 67.0% compare
  2. 88 Iraq 67.0% compare
  3. 88 Jordan 67.0% compare
  4. 91 Algeria 65.0% compare
  5. 91 Costa Rica 65.0% compare
  6. 91 Montenegro 65.0% compare

See the full ranking of 160 places →

More gender data for Malaysia

All data for Malaysia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Malaysia?
Access to anti-retroviral drugs, female in Malaysia was 65.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Malaysia?
The highest recorded value was 71.0% in 2019.
What is the lowest access to anti-retroviral drugs, female recorded in Malaysia?
The lowest recorded value was 1.0% in 2000.
How does Malaysia rank for access to anti-retroviral drugs, female?
Malaysia ranks 91st out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Malaysia?
Over the last ten years it is up 32.7%. The long-run trend across the full record is volatile.
Where does this Malaysia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Malaysia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malaysia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/malaysia/">Access to anti-retroviral drugs, female in Malaysia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.